Number of Shares and Voting Rights of Innate Pharma as of July 1, 2021
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation...Update on Avdoralimab Phase 2 FORCE Trial in COVID-19 Patients with Severe Pneumonia
Investigator-sponsored FORCE trial did not meet primary endpoints Company will stop exploring avdoralimab in COVID-19 Investigator-sponsored avdoralimab clinical trial in inflammation will continue...Innate Pharma Presents Preliminary Data from TELLOMAK Trial Showing Clinical Response for Lacutamab in Mycosis Fungoides
First data set from TELLOMAK establishes safety, clinical responses and skin improvement in patients with mycosis fungoides that express KIR3DL2 Data support continued development of lacutamab for...Innate Pharma to Host Virtual Investor Event to Highlight Progress Against Company Strategy
Company to highlight lacutamab data in mycosis fungoides and share data on its next-generation NK cell engager platform, ANKET™ Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA...Number of Shares and Voting Rights of Innate Pharma as of June 1, 2021
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation...Innate Pharma Presents New Data on Next-Generation NK Cell Engager Platform at FOCIS 2021 Annual Meeting
Proprietary, multi-specific NK cell engager platform, ANKET™, to generate next wave of immunotherapy molecules ANKET is first NK cell engager technology to engage NKp46, CD16, IL 2 variant and tumor...New Lacutamab Data from TELLOMAK Trial to be Showcased in Oral Presentation at Upcoming 16th International Conference on Malignant Lymphoma
First clinical data of mycosis fungoides presented from the TELLOMAK trial Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that...Outcome of Innate Pharma's Annual General Meeting
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced the voting results of its shareholders at the Annual General Meeting (“AGM”), which took...Number of Shares and Voting Rights of Innate Pharma as of May 1, 2021
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation...Innate Pharma Virtual 2021 Annual General Meeting
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) has published the convening notice to the Bulletin des Annonces Légales Obligatoires for its...
